Since its launch, the Fund has made four investments to support innovative CNS-focused companies, and today, on World Mental Health Day, we would like to shine a spotlight on our most recent investment, DAMONA Pharmaceuticals, a company dedicated to creating a new class of therapies for patients living with cognitive deficits associated with depression. By funding innovative research in neuropsychiatry, we are contributing towards the ongoing efforts in finding novel therapies for patients suffering from mental illnesses. Estimates suggest a >25% rise in depressive disorders and a widening treatment gap for mental health illness, especially since the pandemic. Through our growing efforts, we hope to stimulate deeper conversations and greater understanding, while continuing to support new treatments with a promise to improve patient care for mental disorders at a global scale.